Ergoteles’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ergoteles’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27,332	Closed	-$2.83M	–	1283
2022 Q4	$2.83M	Buy	+27,332	New	+$2.57M	0.1%	198
2021 Q3	–	Sell	-48,403	Closed	-$4.04M	–	1235
2021 Q2	$4.04M	Buy	+48,403	New	+$3.84M	0.09%	257
2021 Q1	–	Sell	-169,200	Closed	-$14.8M	–	813
2020 Q4	$14.8M	Buy	+169,200	New	+$13.4M	0.49%	55

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ergoteles's BMRN Position: Q1 2023 in Review

Ergoteles sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 27,332 shares — an estimated $2.83M sold.

Ergoteles first reported a position in BMRN in Q4 2020 and held it in 3 quarters. The position peaked at $14.8M in Q4 2020. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Ergoteles reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 27,332 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $2.83M.
Ergoteles first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Ergoteles's BioMarin Pharmaceuticals position peaked at $14.8M in Q4 2020.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.